A number of other equities analysts also recently commented on the stock. Cowen reduced their price objective on shares of Impel Pharmaceuticals to $40.00 in a research note on Thursday, November 17th. Jonestrading began coverage on shares of Impel Pharmaceuticals in a research note on Wednesday, August 24th. They issued a buy rating and a $26.00 price objective for the company. Finally, Wedbush downgraded shares of Impel Pharmaceuticals from an outperform rating to a neutral rating and reduced their price objective for the stock from $24.00 to $5.00 in a research note on Tuesday, November 15th.
Impel Pharmaceuticals Stock Performance
Shares of NASDAQ:IMPL opened at $2.73 on Monday. The company has a market capitalization of $64.81 million, a price-to-earnings ratio of -0.59 and a beta of 0.04. Impel Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $10.75. The company has a quick ratio of 4.54, a current ratio of 4.97 and a debt-to-equity ratio of 12.07. The firm has a 50 day moving average of $4.44 and a 200 day moving average of $6.69.
Hedge Funds Weigh In On Impel Pharmaceuticals
Impel Pharmaceuticals Company Profile
Impel Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
- Get a free copy of the StockNews.com research report on Impel Pharmaceuticals (IMPL)
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Impel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.